Good news! Cancer is history (soon)!
"... have developed an immunotherapy using a cocktail of messenger RNAs (mRNA) that could potentially transform pancreatic cancer treatment.
The study ... combines immune cytokine and tumor-associated antigen mRNAs into a single injection to treat pancreatic ductal adenocarcinoma.
Approximately 50% of mice with pancreatic cancer treated with the mRNA immunotherapeutic cocktail had complete tumor responses and, more impressively, remained disease-free for a year, even after treatment had stopped.
"It's unheard of to get a response like this in these models of pancreatic cancer," ..."
From the abstract:
"Immunotherapy has limited success in pancreatic ductal adenocarcinoma (PDAC) due to an immune exclusive tumor microenvironment (TME) that lacks many cytokines necessary for Natural Killer (NK) and T cell responses.
Here, we design multiplexed mRNAs encoding interleukins, chemokines, and interferons as a safe and effective cytokine therapy for PDAC.
Intratumoral injection of IL-12, IL-18, CCL5, CXCL10, and IFNβ mRNAs achieves robust yet transient cytokine expression, leading to NK and CD8+ T cell activation and reduced tumor growth and fibrosis in PDAC transplant mouse models.
Combining cytokine with tumor antigen mRNAs enhances dendritic cell antigen presentation and CD8+ T cell priming locally and systemically that prolongs animal survival after a single dose.
Remarkably, nanoparticle encapsulation of the cytokine/antigen mRNA cocktail allows systemic administration and local delivery to autochthonous PDAC tumors in mice, culminating in curative responses in 50% of animals and antigen-reactive T cell persistence.
These results suggest that multiplexed mRNA approaches to deliver cytokines and antigens generally absent in the TME could pave the way for effective immunotherapy in PDAC."
mRNA immunotherapy developed by UMass Chan scientists eliminates pancreatic tumors in mice (original news release)
Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer (open access)
Fig. 2: A multiplexed cytokine mRNA cocktail mobilizes innate and adaptive immunity and reduces tumor growth and desmoplasia in “cold” PDAC-bearing mice.
Fig. 3: Combinatorial cytokine mRNA therapy can achieve robust cytotoxic T cell immunity in a “hot” PDAC model after a single dose.